NPI: 1811158215 · CLYDE, NC 28721 · General Acute Care Hospital · NPI assigned 06/19/2008
Authorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
| Authorized Official | LAWRENCE, CHARLOTTE (SECRETARY) |
| NPI Enumeration Date | 06/19/2008 |
Other providers sharing the same authorized official: LAWRENCE, CHARLOTTE
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 34,243 | $928K |
| 2019 | 32,404 | $882K |
| 2020 | 20,008 | $434K |
| 2021 | 27,522 | $1.03M |
| 2022 | 33,637 | $1.59M |
| 2023 | 41,144 | $1.96M |
| 2024 | 33,492 | $1.95M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14,280 | 11,826 | $2.39M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 11,578 | 9,925 | $1.30M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 14,276 | 12,200 | $1.26M |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 25,187 | 21,151 | $669K |
| 87428 | 6,434 | 5,803 | $472K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 9,213 | 7,894 | $256K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7,721 | 6,463 | $221K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1,565 | 1,279 | $207K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7,774 | 5,983 | $157K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 9,624 | 8,256 | $141K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1,655 | 1,390 | $135K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 18,860 | 16,419 | $132K |
| 80053 | Comprehensive metabolic panel | 16,070 | 13,905 | $121K |
| 97597 | 1,303 | 582 | $93K | |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3,540 | 2,980 | $90K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5,916 | 5,042 | $89K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3,340 | 2,806 | $86K |
| 71046 | Radiologic examination, chest; 2 views | 3,483 | 2,917 | $85K |
| 87631 | 953 | 826 | $73K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3,509 | 3,028 | $72K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1,396 | 1,295 | $58K |
| 71045 | Radiologic examination, chest; single view | 1,483 | 1,203 | $46K |
| 87081 | 4,968 | 4,457 | $42K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1,842 | 452 | $41K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3,179 | 2,577 | $40K |
| 96375 | Therapeutic injection; each additional sequential IV push | 983 | 746 | $30K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1,287 | 900 | $29K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1,265 | 887 | $29K |
| 80306 | 744 | 638 | $27K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1,051 | 879 | $26K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 809 | 692 | $26K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2,830 | 2,286 | $25K |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 905 | 706 | $22K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1,256 | 1,006 | $21K |
| 83690 | 2,768 | 2,334 | $18K | |
| 81001 | 5,652 | 4,775 | $17K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 31 | 26 | $16K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 172 | 87 | $15K |
| 84484 | 1,808 | 1,439 | $15K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1,780 | 1,375 | $13K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 617 | 557 | $13K |
| J7030 | Infusion, normal saline solution , 1000 cc | 3,318 | 2,904 | $12K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 163 | 48 | $11K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 190 | 183 | $10K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 242 | 233 | $10K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 419 | 365 | $9K |
| 84702 | 758 | 598 | $7K | |
| 87807 | 427 | 377 | $7K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 21 | 16 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 84 | 71 | $6K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 150 | 121 | $6K |
| 70450 | Computed tomography, head or brain; without contrast material | 55 | 49 | $5K |
| 83735 | 872 | 646 | $5K | |
| 87070 | 473 | 435 | $5K | |
| 81003 | 1,960 | 1,749 | $4K | |
| 36415 | Collection of venous blood by venipuncture | 1,894 | 1,553 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 92 | 75 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1,158 | 970 | $4K |
| 84703 | 422 | 371 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 167 | 164 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 147 | 131 | $3K |
| 82962 | 734 | 683 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1,032 | 838 | $3K |
| 80061 | Lipid panel | 141 | 131 | $2K |
| J2704 | Injection, propofol, 10 mg | 627 | 585 | $2K |
| 88142 | 119 | 89 | $2K | |
| 99201 | 181 | 174 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 657 | 614 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 70 | 58 | $2K |
| 93970 | 14 | 12 | $1K | |
| 80055 | 44 | 37 | $1K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 35 | 12 | $1K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 12 | 12 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | 85 | 77 | $1K |
| 87186 | 88 | 63 | $846.00 | |
| 86803 | 46 | 39 | $834.62 | |
| 86780 | 41 | 33 | $712.94 | |
| 84443 | Thyroid stimulating hormone (TSH) | 60 | 51 | $643.10 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 438 | 392 | $579.57 |
| 87653 | 14 | 14 | $548.45 | |
| 72110 | 12 | 12 | $532.55 | |
| 87899 | 28 | 25 | $463.99 | |
| 82565 | 124 | 118 | $460.69 | |
| 80048 | Basic metabolic panel (calcium, ionized) | 55 | 53 | $452.71 |
| 82105 | 12 | 12 | $373.51 | |
| 84145 | 15 | 15 | $337.87 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 14 | 12 | $299.20 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 547 | 468 | $294.25 |
| 81025 | 42 | 40 | $267.92 | |
| 82951 | 14 | 12 | $237.84 | |
| 86787 | 15 | 12 | $192.60 | |
| 86702 | 16 | 12 | $167.50 | |
| J3490 | Unclassified drugs | 173 | 111 | $144.30 |
| 86308 | 15 | 14 | $128.53 | |
| 86701 | 16 | 12 | $126.48 | |
| 85610 | 64 | 63 | $115.60 | |
| 83605 | 66 | 12 | $99.69 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 57 | 41 | $90.81 |
| 85652 | 29 | 28 | $53.86 | |
| 85651 | 31 | 28 | $49.66 | |
| 85730 | 12 | 12 | $15.70 | |
| 84450 | 67 | 62 | $7.48 | |
| 84460 | 68 | 63 | $0.55 | |
| 82746 | 16 | 13 | $0.00 | |
| A9270 | Non-covered item or service | 137 | 117 | $0.00 |
| 82607 | 16 | 13 | $0.00 | |
| 80305 | 217 | 154 | $0.00 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 15 | 14 | $0.00 |